Photo by atikahakhtar from unsplash
Apremilast (Otezla®, Celgene France), an oral phosphodiesterase-4 inhibitor, has been approved for treating moderate-to-severe chronic plaque psoriasis in adult patients failing to respond to, or having a contraindication to, or… Click to show full abstract
Apremilast (Otezla®, Celgene France), an oral phosphodiesterase-4 inhibitor, has been approved for treating moderate-to-severe chronic plaque psoriasis in adult patients failing to respond to, or having a contraindication to, or being intolerant to other systemic therapy including cyclosporine, methotrexate or phototherapy. This article is protected by copyright. All rights reserved.
Keywords:
may influence;
methotrexate;
influence choice;
factors may;
choice initiating;
psoriasis
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!